Century Therapeutics, Inc. (IPSC) Reports In-Line Q2 EPS

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), in-line with the analyst estimate of ($0.38).

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• SpaceX sets date for maiden earnings report: Why August 4 is make-or-break
• BMO Capital Starts Insmed (INSM) at Outperform
• First United (FUNC) Tops Q2 EPS by 8c